Entecavir has been approved by CFDA for children
Recently, Entecavir Tablet (Baraclude), developed by Bristol-Myers Squibb (BMS), has been approved by the CFDA for the treatment of patients from 2 to 18 years old with chronic hepatitis B virus infected compensatory liver disease. Hepatitis B is a kind of infectious disease caused by the hepatitis B virus, which targets the liver and can cause a variety of organ damage, it is mainly transmitted b...